Perspectives on long-acting growth hormone therapy in children and adults

Arch Endocrinol Metab. Nov-Dec 2019;63(6):601-607. doi: 10.20945/2359-3997000000190.

Abstract

Growth hormone therapy with daily injections of recombinant human growth hormone has been available since 1985, and is shown to be safe and effective treatment for short stature in children and for adult growth hormone deficiency. In an effort to produce a product that would improve patient adherence, there has been a strong effort from industry to create a long acting form of growth hormone to ease the burden of use. Technologies used to increase half-life include depot formulations, PEGylated formulations, pro-drug formulations, non-covalent albumin binding growth hormone and growth hormone fusion proteins. At present, two long acting formulations are on the market in China and South Korea, and several more promising agents are under clinical investigation at various stages of development throughout the world. Arch Endocrinol Metab. 2019;63(6):601-7.

Publication types

  • Review

MeSH terms

  • Adult
  • Chemistry, Pharmaceutical
  • Child
  • Delayed-Action Preparations
  • Drug Administration Schedule
  • Drug Design
  • Growth Disorders / drug therapy*
  • Human Growth Hormone / administration & dosage*
  • Human Growth Hormone / chemistry
  • Human Growth Hormone / pharmacokinetics
  • Humans

Substances

  • Delayed-Action Preparations
  • Human Growth Hormone